Nature Communications (Sep 2022)

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors

  • Christina Lamers,
  • Xiaoguang Xue,
  • Martin Smieško,
  • Henri van Son,
  • Bea Wagner,
  • Nadja Berger,
  • Georgia Sfyroera,
  • Piet Gros,
  • John D. Lambris,
  • Daniel Ricklin

DOI
https://doi.org/10.1038/s41467-022-33003-7
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 15

Abstract

Read online

Therapeutic modulation of the complement system has gained interest over the past two decades. Here, the authors provide molecular-level insight into the mode-of-action, target selectivity and species specificity of the compstatin family of complement inhibitors, which entered the clinic in 2021.